1. Home
  2. ACOG vs SPRO Comparison

ACOG vs SPRO Comparison

Compare ACOG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.00

Market Cap

129.4M

Sector

N/A

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.19

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
SPRO
Founded
2000
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.4M
124.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ACOG
SPRO
Price
$6.00
$2.19
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$18.00
N/A
AVG Volume (30 Days)
79.2K
350.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$47,977,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$132.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.75
$0.51
52 Week High
$10.88
$3.09

Technical Indicators

Market Signals
Indicator
ACOG
SPRO
Relative Strength Index (RSI) 55.62 39.37
Support Level $4.96 $2.15
Resistance Level $6.72 $2.20
Average True Range (ATR) 0.63 0.09
MACD 0.10 -0.02
Stochastic Oscillator 71.93 20.53

Price Performance

Historical Comparison
ACOG
SPRO

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: